Initiating and Switching ARV Therapy: Clinical Considerations : ViralEd, Inc.

Friday, September 16th 2022 at 12:00 pm EDT

Presenter:

David A. Wohl, MD
Professor - Division of Infectious Diseases

University of North Carolina - Chapel Hill

Site Leader - UNC AIDS Clinical Trial Unit

Co-Director - UNC Viral Hemorrhagic Fever Research Group

Co-Director - NC AIDS Training and Education Center

Chapel Hill, NC

Scoll down to access the program LOG-IN window at the bottom of this page!

Target Audience

This activity is intended for physicians, physician assistants, advanced practice nurses, general practitioners and other health care professionals involved in the treatment and management of patients who have or are at risk of HIV infection.

Learning Objectives

Upon completion of theactivity, participants should be better able to:

Describe the options available for initiating ARV therapy in people with HIV infection
Discuss the data that support the initiation of ARV therapy in various patient populations and circumstances
Identify barriers to successful ARV therapy, such as side effects
Use approaches for switching ARV therapy in people with HIV that maintain viral suppression and reduce barriers to good treatment outcomes
Describe the role of the pharmacist in providing optimal HIV care and in switching ARV therapy

Joint Accreditation Statement:

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and ViralEd, Inc. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Continuing Medical Education:
The Postgraduate Institute for Medicine designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The Postgraduate Institute for Medicine designates this continuing medical education activity for 1.00 contact hour(s)(0.10 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: UAN JA4008162-9999-22-182-L01-P
Type of Activity: Knowledge

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires faculty, planners and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

David Wohl, MD

Fees for Non-CME/CE Services Received Directly from a Commercial Interest: Gilead, Janssen, Viiv.

Postgraduate Institute for Medicine

The PIM planners and others have nothing to disclose. The ViralEd, Inc. planners and others have nothing to disclose.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

FILL OUT THE FORM BELOW TO JOIN OUR PROGRAM

Initiating and Switching ARV Therapy: Clinical Considerations
Your name *
Email address *
Degree/Profession *
Country *
How many participants are watching using your internet connection? *

* Required